Published in P T on May 01, 2014
The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF) | NCT01767909
Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurol (2015) 0.96
Advances in the prevention of Alzheimer's Disease. F1000Prime Rep (2015) 0.89
Role of cerebrospinal fluid biomarkers in clinical trials for Alzheimer's disease modifying therapies. Korean J Physiol Pharmacol (2014) 0.81
Therapeutic strategies for the treatment of tauopathies: Hopes and challenges. Alzheimers Dement (2016) 0.76
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Testing the right target and right drug at the right stage. Sci Transl Med (2011) 3.55
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med (2014) 3.45
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med (2013) 3.25
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement (2013) 2.31
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res (2009) 1.34
Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol (2013) 1.29
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiol Aging (2012) 1.04
Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers Dement (2014) 0.96
Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition. Curr Alzheimer Res (2013) 0.93
MS Treatment Is on the Cusp of Something Big: On the Cusp of Something Big? Biotechnol Healthc (2012) 0.75
Researchers Expand Focus on Progressive Forms Of Multiple Sclerosis: Efforts to Pinpoint the Beginning of Disease May Yield Clues to Treatment. P T (2015) 0.75
Lung cancer research is taking on new challenges: knowledge of tumors' molecular diversity is opening new pathways to treatment. P T (2014) 0.75
Lung Cancer Screening Comes of Age. Manag Care (2015) 0.75
Accolade's expanding clientele likes its emphasis on members. Manag Care (2014) 0.75
Is the USPSTF right about early screening for cognitive impairment? Manag Care (2014) 0.75
Boom times for brain injuries. Manag Care (2015) 0.75
Will biomarkers be next leap forward in RA? Manag Care (2013) 0.75
New FDASIA Legislation Will Help Biotechs. Biotechnol Healthc (2012) 0.75
DSM-5--back to the drawing board? Manag Care (2013) 0.75